[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xinqiao Hospital of Chongqing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":386},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,38,65,85,104,130,157,183,205,224,240,268,286,305,322,345,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100619839","early-phase-1-application-of-mrna-immunotherapy-technology-in-eb-virus-related-diseases-100619839",false,"NCT07349836","Application of mRNA Immunotherapy Technology in EB Virus Related Diseases","Inclusion Criteria:\n\n* 1\\. Male or female patients aged ≥ 18 years old;\n* 2\\. Diagnosed with EBV related diseases through histology or cytology, including but not limited to nasopharyngeal carcinoma, gastric cancer, lymphoma, EBV disease after HSCT etc;\n* 3\\. ECOG physical condition score: 0-2 points;\n* 4\\. Expected survival period ≥ 3 months;\n* 5\\. The main organ functions well, that is, the relevant examination indicators meet the requirements;\n* 6\\. The subject has no pregnancy plan during the treatment period and agrees to voluntarily take effective contraceptive measures during the trial period and within 4 months of stopping treatment, and the pregnancy of women of childbearing age is negative;\n* 7\\. Able to understand and voluntarily sign a written informed consent form before the experiment;\n* 8\\. Able to communicate well with researchers and complete experiments according to the protocol.\n\nExclusion Criteria:\n\n* 1\\. The patient has a history of other tumors in the past, except for the cured skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, gastrointestinal intramucosal carcinoma and other malignant tumors that the researchers think can be included;\n* 2\\. Central nervous system (CNS) tumors or CNS metastases;\n* 3\\. Chest fluid, ascites, and pericardial effusion that require drainage due to clinical symptoms; Hepatic encephalopathy, hepatorenal syndrome, or Child Pugh B or more severe cirrhosis;\n* 4\\. Known to have invasive NK cell leukemia or NK lymphoblastic leukemia\u002Flymphoma; Or accompanied by hemophilic cell syndrome;\n* 5\\. There are any uncontrollable clinical or mental illnesses or other major illnesses that, according to the researcher's assessment, may hinder the provision of informed consent, interfere with the interpretation of the trial results, pose risks to the subjects participating in this trial, or otherwise affect the achievement of the trial objectives;\n* 6\\. Allergic to the experimental drug (including any excipients). Previous history of severe allergies to any medication, food, or vaccine, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc;\n* 7\\. The most recent anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local regional therapy) is less than 4 weeks after the first dose or within 5 half lives of the drug (whichever is shorter), or palliative radiotherapy is less than 2 weeks after the first dose; Patients with adverse reactions related to anti-tumor therapy (excluding hair loss) that have not recovered to NCI CTCAE ≤ 1 or inclusion criteria after previous anti-tumor therapy;\n* 8\\. Subjects who receive systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent doses of other corticosteroids) or other immunosuppressive agents within 14 days prior to their first administration. In the absence of active autoimmune diseases, inhalation or topical use of steroids and adrenal hormone replacement with a dose ≤ 10 mg\u002Fday of prednisone efficacy dose is allowed;\n* 9\\. Within 6 months prior to the first administration, have received mRNA vaccines or lipid nanoparticles (LNP) equivalent nanoparticles for drug delivery;\n* 10\\. Having undergone major surgery within the 4 weeks prior to screening (excluding minor surgeries such as catheter insertion or biopsy surgery as required by the protocol), or the impact of surgery or trauma has been eliminated for less than 14 days prior to enrollment;\n* 11\\. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcohol or drug abuse;\n* 12\\. Known active infections such as hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), syphilis, etc.:\n* 13\\. The researchers believe that there are any other factors that are not suitable for the subjects to enter this trial.","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","EB virus is associated with various epithelial and lymphoid derived tumors, such as Burkitt lymphoma, Hodgkin lymphoma, epithelial derived nasopharyngeal carcinoma, and some gastric cancers. In EBV related tumors, epithelial tumors account for over 80%, with the majority being nasopharyngeal carcinoma and EVB related gastric cancer. Among lymphomas, NK\u002FT-cell lymphoma is the lymphoma most closely associated with EBV infection, accounting for approximately 6%. In the world, the incidence rate of NK\u002FT lymphoma in China is the highest, and it is a malignant lymphoma with rapid development and strong invasion.\n\nmRNA immunotherapy is a promising novel anti-tumor treatment method. Previous basic research and clinical practice have shown that immune drugs prepared using antigen-presenting cells loaded with tumor antigens, CAR-T cells, etc. can produce objective clinical therapeutic effects. Compared with traditional immune drugs, mRNA immune drugs have unique advantages in the field of tumor immunotherapy. They can express and present antigens for a long time, thereby stimulating stronger immune responses and producing cytotoxic T cells (CTLs) that specifically recognize EB virus antigens, exerting anti-tumor effects.\n\nPrevious studies have preliminarily confirmed that the mRNA immunotherapy monotherapy has good safety and tolerability in various tumor populations. Considering that most EBV positive tumor patients have limited treatment options, and that PD-1\u002FL1 inhibitors have shown excellent anti-tumor efficacy in the treatment of various malignant tumors, research on mRNA vaccine monotherapy and its combination with immune checkpoint inhibitors is being conducted to provide more treatment options for patients with EB virus related tumors.",[25],"EBV-associated Tumors","NOT_YET_RECRUITING","2026-01-15",{"date":29,"type":30},"2026-01-20","ACTUAL",{"date":32,"type":19},"2026-01-10",{"date":34,"type":19},"2028-12-31",{"name":36,"class":37},"Xinqiao Hospital of Chongqing","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100619669","phase-3-eptifibatide-for-extended-window-ischemic-stroke-after-thrombolysis-100619669","NCT07347626","Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial","E-TWIST","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Acute ischemic stroke, with the time interval from last known well to hospital presentation being 4.5 to 24 hours.\n3. NIHSS score ≥ 4 before randomization; if large or medium vessel occlusion is present, an NIHSS score ≤ 10 is also required.\n4. Presence of any of the following conditions after completion of standard intravenous thrombolysis:\n\n   1. No significant neurological improvement within 1 hour (defined as a change in NIHSS score ≤ 1 point from baseline).\n   2. Early neurological deterioration within 1 hour of onset (defined as an increase in NIHSS score ≥ 2 points from baseline).\n   3. Neurological fluctuation within 24 hours after symptom onset (defined as an increase in NIHSS score ≥ 2 points from the lowest value post-thrombolysis).\n5. Ability to receive the assigned study drug within 60 minutes after intravenous thrombolysis.\n6. Signed written informed consent obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT or MRI.\n2. Planned endovascular therapy.\n3. Presence of any definite cardioembolic source, including: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, spontaneous echo contrast in the left atrium, or ejection fraction \\\u003C 30%.\n4. Pre-stroke modified Rankin Scale (mRS) score ≥ 2.\n5. Renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002FdL\\]).\n6. Known hypercoagulable state.\n7. Platelet count \\\u003C 100 × 10⁹\u002FL.\n8. Pregnancy or lactation.\n9. Allergy to eptifibatide, other glycoprotein IIb\u002FIIIa inhibitors, aspirin, or clopidogrel.\n10. History of non-atherosclerotic arteriopathy, including moyamoya disease, arterial dissection, or fibromuscular dysplasia.\n11. Pre-existing neurological or psychiatric disease that would preclude accurate neurological assessment.\n12. History of bleeding diathesis, severe cardiac disease, liver disease, or sepsis.\n13. Brain tumor with mass effect on imaging (except for small meningiomas).\n14. Evidence of intracranial arteriovenous malformation or aneurysm with diameter \\> 5 mm on CT or MR angiography.\n15. Current participation in another clinical trial.\n16. Any terminal illness with life expectancy \\\u003C 6 months.\n17. Anticipated inability to complete follow-up.",{"count":47,"type":19},786,[49],"PHASE3","This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.",[52],"Acute Ischemic Stroke",[52,54,55,56],"Intravenous thrombolysis","Eptifibatide","Neurological deterioration",{"date":58,"type":30},"2026-01-16",{"date":60,"type":19},"2026-03-01",{"date":62,"type":19},"2029-12-31",{"name":36,"class":37},6,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},"100619840","early-phase-1-exploratory-study-on-mrna-therapeutic-drug-targeting-cd19-for-the-treatment-of-hematologic-malignancies-100619840","NCT07349849","Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies","Inclusion Criteria:\n\n* 1\\. Age range of 18-70 years old, gender not limited;\n* 2\\. Expected survival time exceeds 12 weeks;\n* 3\\. B-cell lymphoma or lymphocytic leukemia diagnosed with CD19+, with no standard treatment options recommended according to guidelines\n* 4\\. There are assessable lesions (applicable only to lymphoma patients);\n* 5\\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1;\n* May involve other inclusion criteria\n\nExclusion Criteria:\n\n* 1\\. Accompanied by other uncontrolled malignant tumors;\n* 2\\. Previously received chimeric antigen receptor therapy or other transgenic T cell therapy;\n* 3\\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;\n* 4\\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;\n* 5\\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.\n\nMay involve other exclusion criteria","70 Years",{"count":73,"type":19},47,[22],"Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed\u002Frefractory patients still faces significant challenges. CD19 is one of the most clinically valuable targets for B-cell malignant hematological tumors.\n\nThe advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. Lipid nanoparticles (LNP) are currently the most mature non viral delivery platform, capable of protecting mRNA from nuclease degradation, promoting intracellular uptake, and achieving efficient translation in vivo.\n\nThe core of LNP-mRNA technology targeting CD19 is to encapsulate the mRNA encoding specific proteins (such as anti-CD19 related proteins) in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection.",[77],"B-cell Malignancies","RECRUITING",{"date":29,"type":30},{"date":81,"type":19},"2025-12-20",{"date":34,"type":19},{"name":36,"class":37},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":15,"minAge":91,"maxAge":71,"enrollmentInfo":92,"targetDuration":4,"studyType":20,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":4},"100620833","early-phase-1-exploratory-study-on-mrna-therapy-targeting-cd19-for-the-treatment-of-refractory-autoimmune-diseases-100620833","NCT07362758","Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases","Inclusion Criteria:\n\n* 1\\. Age range of 14-70 years old (including threshold), gender not limited;\n* 2\\. KPS score\\>60 points, life expectancy greater than 6 months;\n* 3\\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel;\n* 4\\. Those who can understand this experiment and have signed the informed consent form.\n* 5\\. Before screening (at baseline), corresponding conditions should be met;\n* 6\\. Indications for severe, recurrent, or refractory immune related diseases, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), systemic lupus erythematosus（SLE），systemic sclerosis （SSc） etc., meet the corresponding inclusion criteria; For other types of diseases, researchers will assess whether they meet the inclusion requirements after fully evaluating the risks and benefits based on the patient's treatment needs.\n\nExclusion Criteria:\n\n* 1\\) Study participants who are allergic or hypersensitive to any component of the investigational drug, including those who are allergic to messenger RNA (mRNA) vaccines or other RNA LNP products.\n* 2\\) Merge any active infections that require antibiotic treatment and have not been controlled for at least one week prior to D1 administration.\n* 3\\) Malignant tumors diagnosed within the first 2 years of screening are excluded, except for skin basal cell carcinoma, squamous cell carcinoma, or cervical cancer in situ that has been adequately treated.\n* 4\\) Uncontrolled ischemic heart disease, including unstable angina within the previous 6 months of screening, or evidence of active ischemic heart disease on electrocardiogram.\n* 5\\) New York Heart Association (NYHA) grade III-IV heart failure.\n* 6\\) Study participants with combined active hepatitis B virus (HBV) infection \\[defined as surface antigen (HBsAg) positive and HBV DNA positive (detected by PCR)\\].\n* 7\\) Study participants with combined active hepatitis C virus (HCV) infection (defined as HCV RNA positive (detected by PCR), regardless of anti HCV antibody status).\n* 8\\) Human immunodeficiency virus (HIV) infection or history of HIV infection.\n* 9\\) Study participants who tested positive for Treponema pallidum specific antibodies.\n* 10\\) There may be active infection of Mycobacterium tuberculosis.\n* 11\\) Women who are currently pregnant, breastfeeding, or planning to become pregnant.\n* 12\\) Combining severe or recently (\\\u003C2 months) diagnosed medical conditions, as determined by the researchers, may affect the study participants' tolerance to the study drug or their ability to complete the study process.\n* 13\\) Received attenuated live vaccine or protein subunit vaccine within 30 days prior to the first study medication.","14 Years",{"count":73,"type":19},[22],"Autoimmune diseases, such as immune thrombocytopenia (ITP), immune hemolytic anemia (AIHA), systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), and systemic sclerosis (SSc), are a type of chronic disabling disease characterized by the immune system mistakenly attacking the body itself, leading to tissue damage and organ dysfunction.Autoimmune hematological diseases, especially difficult to treat autoimmune diseases, are a type of disease that is difficult to treat and has a significant impact on patients' lives. Although there are various treatment methods currently available, there are still many limitations to autoimmune sexually transmitted diseases that aim for long-term remission, and further research and breakthroughs are urgently needed.\n\nThe advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. Lipid nanoparticles (LNP) are currently the most mature non viral delivery platform, capable of protecting mRNA from nuclease degradation, promoting intracellular uptake, and achieving efficient translation in vivo.\n\nThe core of LNP-mRNA technology targeting CD19 is to encapsulate the mRNA encoding specific proteins (such as anti-CD19 related proteins) in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection.",[96],"Autoimmune Diseases","2026-01-14",{"date":99,"type":30},"2026-01-23",{"date":101,"type":19},"2026-01-01",{"date":34,"type":19},{"name":36,"class":37},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":20,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100591967","phase-3-intravenous-rhtnk-tpa-before-stroke-thrombectomy-in-the-extended-time-window-100591967","NCT06987305","Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window","Intravenous rhTNK-tPA Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the BRIDGE-TNK EXTEND Randomized, Placebo-controlled, Double-blind Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke presenting within 4.5-24 hours of last known well;\n3. No significant pre-stroke functional disability: for age \\\u003C80 years, pre-stroke modified Rankin scale (mRS) ≤2; for age ≥80 years, prestroke mRS ≤1;\n4. Baseline NIHSS score ≥5;\n5. Imaging criteria of BOTH:\n\n   1. Occlusion on CTA\u002FMRA in one of the following vessels: M1\u002FM2 segment of middle cerebral artery, A1 segment of anterior cerebral artery, V4 segment of vertebral artery, basilar artery, or P1 segment of posterior cerebral artery. For A1, or P1 occlusions, vessel diameter must be ≥0.75 mm;\n   2. For anterior circulation occlusion: CTP\u002FMRP demonstrating mismatch ratio ≥1.8, absolute mismatch volume ≥15 mL, and ischemic core volume \\\u003C70 mL; OR have a mismatch between the presence of an abnormal signal on MRI diffusion-weighted imaging and no visible signal change on FLAIR. For posterior circulation occlusion: pc-ASPECTS score ≥6.\n6. Plan to received endovascular thrombectomy;\n7. The patient or their legal representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT\u002FMRI;\n2. Already received intravenous thrombolytic after index stroke.;\n3. Pregnancy or lactation;\n4. Concurrent participation in other investigation drug clinical trials;\n5. Arterial tortuosity or other vascular anomalies precluding endovascular access to target vessel;\n6. Pre-existing neurological\u002Fpsychiatric disorders interfering with neurological assessment;\n7. Space-occupying intracranial tumors (except small meningiomas ≤3 cm);\n8. Intracranial aneurysm or arteriovenous malformation;\n9. Terminal illness with life expectancy \\\u003C6 months;\n10. Anticipated inability to complete follow-up assessments.",{"count":112,"type":19},820,[49],"This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhTNK-tPA enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhTNK-tPA increases the risk of symptomatic intracranial hemorrhage and mortality.\n\nParticipants will be randomized to receive either a single bolus of rhTNK-tPA (0.25 mg\u002Fkg, max 25 mg) or matching placebo administered intravenously over 5 seconds. Key assessments include repeat neuroimaging (CT\u002FCTA or MRI\u002FMRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.",[116],"Stroke, Acute Ischemic",[118,119,120],"acute ischemic stroke","endovascular treatment","rhTNK-tPA","2025-12-24",{"date":123,"type":30},"2025-12-31",{"date":125,"type":30},"2025-10-21",{"date":127,"type":19},"2028-02-29",{"name":36,"class":37},4,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":20,"phases":140,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":84},"100495219","phase-2-intravenous-tirofiban-versus-alteplase-before-mechanical-thrombectomy-in-stroke-100495219","NCT05728333","Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke","Intravenous Adjuvant With Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Acute Ischemic Stroke Patients With Large Vessel Occlusion: a Multicenter, Open Label, Randomized Controlled Trial.","ADJUVANT","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Presenting with acute ischemic stroke symptom.\n3. Time from onset to hospital arrival:\n\n   * (1) within 4.5 hours\n   * (2) 4.5-9.0 hours, image inclusion criteria for the EXTEND trial must be met\n   * (3) \\> 4.5 hours but within 24 hours, image inclusion criteria for the WAKE-UP trial must be met.\n4. Eligible for intravenous thrombolysis.\n5. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery, vertebrobasilar artery confirmed by CTA, MRA, or DSA.\n6. Informed consent obtained from patients or their legal representatives.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage (the presence of micro-bleeds is allowed);\n2. Contraindications of IV rt-PA or tirofiban;\n3. Contraindication to radiographic contrast agents, nickel, titanium metals or their alloys;\n4. Arterial tortuosity and\u002For other arterial disease that would prevent the device from reaching the target vessel;\n5. Patients with a preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;\n6. CT or MRI evidence of mass effect or intracranial tumor (except small eningioma);\n7. CT or MRI evidence of cerebral vasculitis;\n8. CTA or MRA evidence of intracranial arteriovenous malformations or aneurysms;\n9. Any terminal illness with life expectancy less than 6 months.",{"count":139,"type":19},800,[141,49],"PHASE2","In patients with acute ischemic stroke secondary to large vessel occlusion, the role of intravenous adjunctive medications, such as tirofiban, or alteplase before endovascular thrombectomy has not been well investigated. This trial aim to evaluate the efficacy and safety of intravenous tirofiban versus alteplase for acute ischemic stroke patients with large vessel occlusion piror to endovascular thrombectomy.",[116],[145,146,147,148],"endovascular thrombectomy","large vessel occlusion","intravenous thrombolysis","tirofiban","2025-12-18",{"date":151,"type":30},"2025-12-26",{"date":153,"type":30},"2023-11-28",{"date":155,"type":19},"2026-07-31",{"name":36,"class":37},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":20,"phases":166,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},"100457001","a-randomized-trial-of-imaging-selection-modalities-for-stroke-thrombectomy-no-select-100457001","NCT05230914","A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)","Simple Imaging Versus Standard Imaging Selection in Stroke Patients for Endovascular Treatment: the NO-SELECT Randomized Trial","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. The interval time from last known well to hospital arrival is within 24 hours;\n3. Acute stroke confirmed by clinical symptoms or imaging examination;\n4. Field Assessment Stroke Triage for Emergency Destination (FAST ED) ≥4;\n5. Written informed consent is obtained from patients and\u002For their legal representatives.\n\nExclusion Criteria:\n\n1. Allergy to radiographic contrast agents, or nitinol devices;\n2. Currently pregnant or lactating (women patients);\n3. Arterial tortuosity and\u002For other arterial disease that would prevent the device from reaching the target vessel;\n4. Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;\n5. Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);\n6. Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;\n7. Intracranial aneurysm, arteriovenous malformation;\n8. Any terminal illness with life expectancy less than 6 months;\n9. Unlikely to be available for 90-day follow-up.",{"count":165,"type":19},1846,[167],"NA","Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy.\n\nThe newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP\u002FMRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.",[170,171],"Stroke, Ischemic","Stroke, Acute",[119,146,118,173,174,175],"computed tomography perfusion","non-contrast computed tomography","Alberta Stroke Program Early CT score",{"date":151,"type":30},{"date":178,"type":30},"2024-12-12",{"date":180,"type":19},"2027-10-31",{"name":36,"class":37},8,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":20,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":84},"100588921","phase-2-a-study-on-exploring-the-abscopal-effect-induced-by-different-radioimmunotherapy-combination-patterns-in-the-treatment-of-non-small-cell-lung-cancer-with-multiple-metastases-100588921","NCT06947694","A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","A Prospective, Multicenter, Umbrella Design Clinical Study on the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","Inclusion Criteria:\n\n* Patient must meet all of the following inclusion criteria to be enrolled in this study:\n\n  1. Non-small cell lung cancer diagnosed initially through pathological histology.\n  2. There are 3-6 metastatic lesions.\n  3. No brain metastasis or the lesions are stable.\n  4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names).\n  5. ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months.\n  6. Aged between 18 and 75 years old.\n  7. Evaluated by PET-CT (including FDG and FMISO, not mandatory).\n  8. No contraindications for immunotherapy and radiotherapy.\n  9. The informed consent form has been signed.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria are not eligible for enrollment in this study:\n\n  1. Those with severe dysfunction of vital organs (heart, liver, kidney).\n  2. Those accompanied by other malignant tumors.\n  3. Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months.\n  4. Those with a history of mental illness.\n  5. And other situations in which the researchers deem it inappropriate for the subjects to participate in the study.","75 Years",{"count":192,"type":19},427,[141],"It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. The main objective is to find the optimal organ combination and the best radioimmunotherapy combination pattern.",[196],"NSCLC Stage IV Without EGFR\u002FALK Mutation","2025-07-16",{"date":199,"type":30},"2025-07-22",{"date":201,"type":30},"2025-07-02",{"date":203,"type":19},"2027-12-31",{"name":36,"class":37},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":212,"targetDuration":4,"studyType":20,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":84},"100589394","phase-2-study-on-the-optimal-combination-pattern-of-the-combined-treatment-of-radiotherapy-and-immunotherapy-for-the-abscopal-effect-in-non-small-cell-lung-cancer-nsclc-with-multiple-metastases-100589394","NCT06953843","Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases","An Umbrella Trial of Combining Different Radiotherapy Fractionation Patterns With Immunotherapy for Multiple Metastases of Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patient must meet all of the following inclusion criteria to be enrolled in this study:\n\n  1. Non-small cell lung cancer confirmed by pathological histology.\n  2. More than 3 metastatic lesions.\n  3. No brain metastases or stable lesions.\n  4. Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).\n  5. Performance status (PS) score of 0-1, with an expected survival period of more than 3 months.\n  6. Age between 18 and 75 years old.\n  7. Assessment by PET-CT (including FDG and FMISO, not mandatory).\n  8. No contraindications to immunotherapy and radiotherapy.\n  9. Signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria are not eligible for enrollment in this study:\n\n  1. Those with severe dysfunction of important vital organs (heart, liver, kidney).\n  2. Those accompanied by other malignant tumors.\n  3. Uncontrolled heart diseases or myocardial infarction within the past 6 months.\n  4. Those with a history of mental illness.\n  5. Other situations in which the researcher deems it inappropriate for the subject to participate in the study.",{"count":213,"type":19},366,[141],"This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.",[196],"2025-07-11",{"date":219,"type":30},"2025-07-14",{"date":221,"type":19},"2025-07-09",{"date":203,"type":19},{"name":36,"class":37},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":230,"targetDuration":4,"studyType":20,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":84},"100537555","phase-2-thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer-100537555","NCT06279351","Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue\u002Fcytology and genetic testing;\n2. Physical state is good: PS 0-2;\n3. Expected survival of more than 3 months;\n4. Aged 18-75 years old;\n5. Have not received systematic chemotherapy before;\n6. Did not receive cetuximab treatment;\n7. Liver, kidney and bone marrow functions are basically normal;\n8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;\n9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunction of vital organs (heart, liver, kidney);\n2. Patients with other malignant tumors;\n3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);\n4. In the active phase of acute or chronic infectious diseases;\n5. People with a clear history of drug allergy or allergic constitution;\n6. Patients participating in other clinical trials;\n7. Other conditions in which the patient was considered inappropriate to participate in the study.",{"count":231,"type":19},96,[141],"1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.\n2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.",[228],{"date":219,"type":30},{"date":237,"type":30},"2024-08-11",{"date":123,"type":19},{"name":36,"class":37},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":247,"sex":15,"minAge":16,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":258,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100509108","omitting-clinical-target-volume-in-radical-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-100509108","NCT05909137","Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer","Feasibility of Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* •Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable\n\n  * ECOG whole body status (performancestatus,PS) level 0 or 1\n  * The estimated survival time is more than 12 weeks, 18 \\~80 years old\n  * Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count \\> 1,500\u002F MCL Heathko-Pilot Oncology Research Fund; ② Platelet \\> 50,000\u002F MCL; ③ Total bilirubin \\\u003C 1.5 times of the normal upper limit value; ④AST(SGOT)\u002FALT(SGPT) \\\u003C 2.5 times of the normal upper limit; ⑤ Serum creatinine \\\u003C 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range\n  * Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug\n  * Understand and voluntarily sign written informed consent\n  * The investigator judged that the patient had good compliance\n\nExclusion Criteria:\n\n* Malignant pleural\u002Fpericardial effusions, previous thoracic radiotherapy or chemotherapy\n* Uncontrolled concurrent diseases, including but not limited to symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, liver insufficiency, renal insufficiency, uncontrolled diabetic blood sugar, arrhythmia, mental illness or social condition, etc.\n* Pregnant or nursing women\n* The patient has no history of intracranial hemorrhage or spinal cord hemorrhage\n* HIV-positive patients receiving combination antiretroviral therapy\n* Active tuberculosis\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Prior allogeneic stem cell or solid organ transplantation\n* Researchers determine other conditions that may affect the conduct of clinical studies and the determination of their findings",true,"80 Years",{"count":250,"type":19},60,"OBSERVATIONAL","Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis.\n\nThe purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.",[254,255,256,257],"Immunotherapy","Intensity Modulated Radiation Therapy","Radiotherapy","NSCLC",[259,260,261],"IMRT","immunotherapy","CTV",{"date":219,"type":30},{"date":264,"type":19},"2026-02",{"date":266,"type":19},"2026-12",{"name":36,"class":37},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":275,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":285,"locationsCount":84},"100505505","a-real-world-study-of-the-efficacy-and-safety-of-icis-as-first-line-therapy-for-advanced-malignancies-100505505","NCT05862259","A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies","A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies","Inclusion Criteria:\n\n1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.\n2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.\n3. the stage IV according to the eighth edition of IASLC.\n4. PS 0-2, the expected survival \\> 3 months.\n5. the age of 18-75 years.\n6. no contraindication to treatment with immune checkpoint inhibitors.\n\nExclusion Criteria:\n\n1. the patients' compliance was poor, which violated the rules of the trial;\n2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ;\n3. the patients with other malignant tumors;\n4. the researchers considered that the patients should not participate in other conditions of the trial.",{"count":276,"type":19},120,"In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy",[279,254,280],"Malignant Tumor","Artificial Intelligence",{"date":219,"type":30},{"date":283,"type":30},"2023-08-10",{"date":123,"type":19},{"name":36,"class":37},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":293,"targetDuration":4,"studyType":20,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":304},"100497204","efficacy-and-safety-of-super-hyperfractionation-pulse-radiotherapy-combined-with-icis-for-advanced-nsclc-100497204","NCT05754203","Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC","Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With Immune Checkpoint Inhibitor for Advanced Non-small Cell Lung Cancer.","Inclusion Criteria\n\n1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.\n2. Participants diagnosed with stage IIIB or above non-small cell lung cancer confirmed by histopathology (whether newly diagnosed or not) meet the requirements of SBRT radiotherapy (mass limited, less than 5 cm) and immune checkpoint inhibitor therapy (according to CSCO guidelines).\n3. Age ≥ 18 and less than 75.\n4. Eastern Cooperative Oncology Group Performance Status Score (ECOG PS) 0-3.\n\nExclusion Criteria\n\n1. The participant's compliance is poor and the test regulations are violated.\n2. Dysfunction of important organs of liver and kidney, such as myocardial infarction, angina pectoris, and significant increase of liver transaminase.\n3. Any disease requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment.\n4. Serious infection within 4 weeks before enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia.\n5. Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic therapy within 14 days before enrollment.\n6. Participants with untreated chronic hepatitis B or HBV carriers with hepatitis B virus (HBV) DNA ≥ 500 IU\u002FmL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B, HBsAg carriers, treated and stable hepatitis B carriers (HBV DNA \\\u003C 500 IU\u002FmL), and cured hepatitis C patients can be included in the group.\n7. Known history of HIV infection.\n8. Receive any other investigational drug treatment or participate in other clinical trials within 28 days.\n9. There are no contraindications to stereotactic radiotherapy and immune checkpoint inhibitors.",{"count":18,"type":19},[167],"Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance tumor killing, protect normal tissues, reduce immune cell damage and enhance tumor immunogenicity at the same time, and play a stronger immunopotentiation effect in combined immunotherapy. Thereby inducing a stronger abscopal effect of radiotherapy.",[297,298,256],"Lung Cancer","Immune Checkpoint Inhibitor",{"date":219,"type":30},{"date":301,"type":30},"2023-08-01",{"date":60,"type":19},{"name":36,"class":37},2,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":312,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":321,"locationsCount":84},"100476646","an-observational-clinical-study-of-stereotactic-radiotherapy-for-advanced-non-small-cell-lung-cancer-with-stable-disease-after-pd-1-inhibitor-treatment-100476646","NCT05486650","An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment","An Observational Clinical Study of Increasing Stereotactic Radiotherapy in Patients With Advanced Non-small Cell Lung Cancer After Treatment With PD-1 Inhibitors And Evaluation of Stable Disease","Inclusion Criteria:\n\n1. Informed consent has been signed, and according to the judgment of the investigator, the patient can comply with the study protocol;\n2. Patients with stage IIIB, IIIC and stage IV NSCLC (according to the definition of the 8th edition of the American Joint Commission on cancer), who have not been treated and cannot receive radical surgery or radiotherapy confirmed by histopathology, received 3-4 cycles of PD1 antibody ± chemotherapy in the early stage, and the efficacy was evaluated as SD;\n3. Previously, no EGFR sensitive mutation and ALK, ROS1 gene fusion mutation were detected based on tissue examination;\n4. There are measurable lesions evaluated by researchers according to RECIST version 1.1;\n5. The physical state score (ECOG PS) of the eastern cancer cooperation group was 0-1;\n6. Good cardiopulmonary function\n\nExclusion Criteria:\n\n1. The patient's compliance is poor and violates the test regulations;\n2. Patients with positive driver gene are known to carry EGFR mutation or ALK, ROS1 gene translocation;\n3. There are dysfunction of important organs of liver and kidney, such as myocardial infarction, angina pectoris, liver transaminase significantly increased;\n4. Serious adverse drug reactions occurred during induction;\n5. Have suffered from any disease requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days before enrollment;\n6. Severe infection occurred within 4 weeks before enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia;\n7. Severe chronic or active infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic treatment within 14 days before enrollment;\n8. Have a history of interstitial lung disease, non infectious pneumonia or poorly controlled diseases, including pulmonary fibrosis, acute lung disease, etc;\n9. Untreated patients with chronic hepatitis B, HBV carriers with hepatitis B virus (HBV) DNA ≥ 500 iu\u002Fml, or patients with active hepatitis C virus (HCV) should be excluded;\n10. Known history of HIV infection;\n11. Received any other trial drug treatment or participated in other clinical trials within 28 days.",{"count":313,"type":19},20,"After the treatment of advanced non-small cell lung cancer with immune checkpoint inhibitor PD-1\u002FPD-L1 monoclonal antibody, if the treatment response of complete response (CR) or partial response (PR) can be achieved in the early stage, the patients are expected to obtain a better long-term survival rate. Radiotherapy can synergistically improve the effect of immunotherapy. Therefore, we propose a hypothesis: in patients with advanced lung cancer, if only stable disease (SD) is achieved after PD-1 antibody immunotherapy in the early stage, by increasing the stereotactic radiotherapy (SBRT) for primary or metastatic lesions, in order to improve the mechanism of tumor antigen release, promote the activation and activation of effector T cells, and increase the sensitivity of immunotherapy, so as to achieve the goal of early improvement of objective remission rate (ORR). It is expected to improve the long-term survival rate of patients.",[316],"Non Small Cell Lung Cancer",{"date":219,"type":30},{"date":319,"type":30},"2022-08-01",{"date":155,"type":19},{"name":36,"class":37},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":248,"enrollmentInfo":329,"targetDuration":4,"studyType":20,"phases":330,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":84},"100474218","phase-1-single-cell-sequencing-of-blf-to-guide-the-treatment-of-radiation-pneumonitis-or-immune-checkpoint-inhibitor-pneumonitis-100474218","NCT05455034","Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis","Single-cell Sequencing of Bronchoalveolar Lavage Fluid to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis","Inclusion Criteria:\n\n1. Informed consent has been signed, and according to the judgment of the investigator, the patient can comply with the study protocol and sign the written informed consent;\n2. NSCLC patients who have been clinically diagnosed with RP or CIP after histopathologically confirmed radiotherapy or immunocheckpoint inhibitor treatment and have not received glucocorticoid or other drugs.\n3. ≥18 years old, less than 75 years old;\n4. ECOG PS score 0-3 in the Eastern Tumor Collaboration group;\n5. Patients without contraindications to alveolar lavage;\n\nExclusion Criteria:\n\n1. Poor patient compliance and violation of test regulations;\n2. Liver and kidney dysfunction, such as myocardial infarction, angina pectoris, liver transaminase significantly increased;\n3. Had any medical condition requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment;\n4. Severe infection occurred within 4 weeks prior to enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia;\n5. Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic treatment within 14 days prior to enrollment;\n6. Untreated patients with chronic hepatitis B, HBV carriers with HBV DNA≥ 500 IU\u002FmL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Non-active hepatitis B, surface antigen (HBsAg) carriers, treated and stable hepatitis B carriers (HBV DNA \\& LT; 500 IU\u002FmL), patients with cured hepatitis C could be enrolled;\n7. Known history of HIV infection;\n8. Received any other investigational drug or participated in any other clinical trial within 28 days.",{"count":18,"type":19},[331,141],"PHASE1","A multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. Find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. Specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.",[334],"Pneumonitis",[336,337,338,339],"Single-cell Sequencing","Radiation Pneumonitis","Immune Checkpoint Inhibitor Pneumonitis","Bronchoalveolar Lavage Fluid",{"date":219,"type":30},{"date":301,"type":30},{"date":343,"type":19},"2025-12-30",{"name":36,"class":37},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":190,"enrollmentInfo":352,"targetDuration":4,"studyType":20,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":304},"100450619","phase-2-toripalimab-combined-with-radiotherapy-in-the-treatment-of-oligometastatic-nasopharyngeal-carcinoma-100450619","NCT05147844","Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma","Antitumor Activity of Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma: A Single-arm, Multicenter Study","Inclusion Criteria:\n\n1. Must have signed written informed consent and able to comply with study procedure\n2. 18-75 years old\n3. Histologically or cytologically confirmed nasopharyngeal carcinoma\n4. Pathology or imaging confirmed metastatic nasopharyngeal carcinoma.( Clinical stage of IVB according to the 8th edition of AJCC)\n5. Imaging (preferred PET-CT) confirmed oligometastatic NPC (defined as ≤5 metastatic lesions, ≤2 metastatic organs)\n6. Have not received any treatment for metastatic nasopharyngeal carcinoma.\n7. Unsuitable or unwilling to receive chemotherapy according to the judgment of investigator.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-1\n9. Estimated life ≥ 6 month\n10. At least 1 measurable lesions according to RECIST v1.1\n11. Adequate organ function, defined as achieving the following laboratory test results within 7 days before enrollment: ANC≥1.5×10\\^9\u002FL，PLT≥100×10\\^9\u002FL，Hb≥90g\u002FL((Have not accepted blood transfusion or growth factors within 14 days)；the international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; activated partial thromboplastin time(APTT) ≤1.5 × ULN；serum creatinine≤1.5×ULN or estimated glomerular filtration rate(GFR) ≥ 60 mL\u002Fmin\u002F1.73 m2; total bilirubin≤1.5×ULN（total bilirubin\\\u003C3×ULN for patients with Gilbert syndrome）; AST and ALT ≤ 2.5×ULN (AST and ALT ≤ 2.5×ULN for patients with liver metastasis);\n\nExclusion Criteria:\n\n1. Allergy to any component of toripalimab\n2. With any active autoimmune disease or a history of autoimmune disease that may relapse\n\n   Note: Patients with the following diseases were not excluded and should be further screened:\n\n   Controlled type 1 diabetes; Hypothyroidism (could be controlled just by hormone replacement therapy); Controlled celiac disease; Skin diseases that do not require systemic treatment (e.g. vitiligo, psoriasis, alopecia); Any other disease which is not expected to be relapsed without external stimulate\n3. Any active malignancy ≤ 2 years before randomization except for the specific cancer under investigation in this study and any locally relapsed cancer that has been cured after treatment (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)\n4. Received corticosteroid therapy at a dose ≥ 10 mg prednisone per day or any other systemic immunosuppressive therapy within 14 days prior to enrollment.\n5. Patient with uncontrolled diabetes, or abnormal potassium, sodium or corrected calcium levels (≥ grade 1) after receiving standard treatment, or ≥ grade 3 hypoalbuminemia within 14 days prior to enrollment\n6. Patient with a history of interstitial lung disease, non-infectious pneumonia or uncontrollable diseases, including pulmonary fibrosis, acute lung disease, hypertension, etc.\n7. Evidence of severe chronic or active infections (including tuberculosis infection) requiring systemic antibiotics, antibacterial or antiviral therapy within 14 days prior to enrollment\n8. Patient with a history of HIV infection\n9. Evidence of contraindications of immunotherapy or radiotherapy\n10. Patient with untreated chronic hepatitis B or HBV-DNA≥ 500 IU\u002FmL, or active hepatitis C.\n\n    Note: Patients with inactive infection of hepatitis B surface antigen (HBsAg), stable hepatitis B after treatment (HBV DNA \\\u003C 500 IU\u002FmL）and cured hepatitis C could be included.\n11. Have undergone any operation requiring general anesthesia within 28 days prior to enrollment\n12. Previous allogeneic stem cell transplantation or organ transplantation\n13. Patient with any of the following cardiovascular risk factors: Cardiogenic chest pain within 28 days prior to enrollment, which is defined as moderate pain that limits instrumental activities of daily life; Symptomatic pulmonary embolism within 28 days prior to enrollment; Acute myocardial infarction within 6 months prior to enrollment; Grade III or IV disease according to the New York Heart Association within 6 months prior to enrollment;≥ Grade 2 ventricular arrhythmias within 6 months prior to enrollment or the first administration; With a history of cerebrovascular accident within 6 months prior to enrollment or the first administration\n14. Grade 2 peripheral nerve disease according to NCI-CTCAE V5.0\n15. Underlying medical conditions (including abnormal laboratory test values) that: affect drug administration; affect the interpretation of toxicity or AE; lead to poor compliance; alcohol or drug abuse or dependence\n16. Participate in another interventional clinical study at the same time",{"count":18,"type":19},[141],"The aim of the study was to determine the efficacy and safety of toripalimab combined with radiotherapy in the treatment of oligometastatic nasopharyngeal carcinoma",[356],"Nasopharyngeal Carcinoma",{"date":219,"type":30},{"date":359,"type":30},"2022-03-01",{"date":60,"type":19},{"name":36,"class":37},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":20,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100524488","role-of-hypothermia-in-endovascular-stroke-thrombectomy-100524488","NCT06109376","Role of Hypothermia in Endovascular Stroke Thrombectomy","Efficacy and Safety of Endovascular Thrombectomy With Versus Without Hypothermia in Acute Large Vessel Occlusion Stroke: a Randomized Controlled Trial","COOLING","Inclusion Criteria:\n\n1. Aged ≥ 18 years or more;\n2. acute ischemic stroke within 24 hours from onset to randomization;\n3. NIHSS ≥6 points before randomization;\n4. Internal carotid artery, or the middle cerebral artery M1 or M2 occlusion confirmed by CTA\u002FMRA\u002FDSA;\n5. Baseline ASPECTS score ≥ 3 and ≤8, or cerebral infarction core volume \\\u003C 100ml;\n6. The patient decides to undergo endovascular therapy;\n7. The patient or patient's representative signs a written informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage;\n2. Currently pregnant or lactating (women patients);\n3. Allergy to radiographic contrast agents, or nitinol devices;\n4. Arterial tortuosity and\u002For other arterial disease that would prevent the device from reaching the target vessel;\n5. Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);\n6. Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;\n7. Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n8. Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;\n9. Intracranial aneurysm, arteriovenous malformation;\n10. Any terminal illness with life expectancy less than 6 months;\n11. Participating in other clinical trials.",{"count":371,"type":19},200,[167],"Reducing or suspending the increase of the infarcted core, i.e., \"freezing\" the ischemic penumbra, may help improve the efficacy of mechanical thrombectomy. Hypothermia effectively reduces the metabolic level of brain tissue, may prolong the time window for recanalization therapy, and its multi-target therapeutic effect make it one of the most promising neuro-protection approach.\n\nIn recent years, hypothermia has been increasingly used to treat acute ischemic stroke. However, its role in acute ischemic stroke is unclear.\n\nThe objective of this trial is to investigate whether hypothermia combined with endovascular thrombectomy could add additional benefit without increasing the risk of adverse events such as pneumonia, intracerebral hemorrhage, and mortality.",[116],[145,376,146,377],"hypothermia","randomized controlled trial","2023-10-25",{"date":380,"type":30},"2023-10-31",{"date":382,"type":19},"2023-12-01",{"date":384,"type":19},"2027-03-31",{"name":36,"class":37},""]